Lincoln Pharma holds 32nd AGM: Declares ₹1.80 dividend, reappoints directors
Lincoln Pharmaceuticals Limited's 32nd AGM on September 30, 2026, approved a dividend of ₹1.80 per share for FY25-26. Directors Hashmukh I. Patel and Munjal Mahendrabhai Patel were reappointed. The company adopted its FY25-26 financial statements and ratified auditor remuneration for FY26-27.
The declaration of dividend and reappointment of directors are significant events for shareholders, impacting their investment.
The company declared a dividend and reappointed directors, indicating stability and positive returns for shareholders.
Lincoln Pharmaceuticals Limited held its 32nd Annual General Meeting (AGM) on September 30, 2026, commencing at 11:00 AM IST. The meeting, conducted via video conferencing, saw the attendance of 80 shareholders. Mr. Mahendra G. Patel chaired the meeting.
The AGM agenda included the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026. Shareholders approved a dividend of ₹1.80 (18%) per equity share for the financial year 2025-26. Additionally, Mr. Hashmukh I. Patel and Mr. Munjal Mahendrabhai Patel, who were retiring by rotation, were reappointed as directors.
The shareholders also ratified the remuneration payable to Kiran J. Mehta & Co., Cost Accountants, for the financial year ending March 31, 2027. The auditors' and secretarial audit reports did not contain any qualifications. Remote e-voting was available from September 26 to September 29, 2026, with voting also conducted during the AGM. The results of the voting are to be submitted by the scrutinizer within two working days of the AGM's conclusion. The meeting concluded at 11:40 AM IST.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.